Big congratulations to our portfolio company Resistell for recruiting first patients to their multicenter clinical study in Switzerland (Lausanne), Spain (Madrid) and Austria (Innsbruck) with the aim to assess the sensitivity, specificity, accuracy and time to result of the Resistell Phenotech device in testing the antibiotic susceptibility of Gram-negative bacteria, including E. coli and K. pneumoniae, to clinically relevant antibiotics.
Resistell_Press_Release_February_2023
About HEMEX
HEMEX is a CRO providing clinical services to European biotech and medtech companies, assisting them throughout the clinical development process to ensure that products reach the market swiftly. Located in the Basel region, a major life sciences hub, and with offices in Germany and Benelux, we are well positioned to serve small and medium enterprises (SMEs) with multinational clinical projects. The comprehensive package of services we provide includes clinical operations, quality management, regulatory guidance, grant writing services, and fundraising options. At HEMEX, we guarantee fast and clear communication, local accessibility, and transparency to meet the objectives of our clients. For more information, visit https://hemex.ch/